Analytical Data
-
Gene name
WT1
- Application
-
Alternative Names
WT1；Wilms tumor Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P19544
-
Expression Region
1-449aa
-
AA Sequence
MGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSLGGPAPPPAPPPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAGACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPSYGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTGSQALLLRTPYSSDNLYQMTSQLECMTWNQMNLGATLKGVAAGSSSSVKWTEGQSNHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSASETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSRSDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCRWPSCQKKFARSDELVRHHNMHQRNMTKLQLAL
-
Molecular Weight
51.2kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
WT1 (Wilms' Tumor 1) is a transcription factor that plays a crucial role in kidney and gonadal development, and its mutation or aberrant expression is associated with various cancers, particularly Wilms' tumor and leukemia. Research on WT1 recombinant protein has gained momentum due to its potential as a diagnostic marker and therapeutic target in cancer treatment. The WT1 protein is notably involved in regulating cell growth and differentiation, which directly links it to tumorigenesis. Studies have shown that WT1 is overexpressed in many types of tumors, making it a promising candidate for immunotherapy. The generation of WT1 recombinant proteins facilitates the investigation of its biological functions, interactions with other cellular pathways, and mechanisms of action. Advances in recombinant DNA technology have enabled the production of WT1 protein in sufficient quantities, allowing for detailed structural and functional analyses. By creating WT1-based vaccines or targeted therapies, researchers aim to harness the immune system to recognize and eliminate cancer cells expressing this protein. Furthermore, the study of WT1 recombinant protein has important implications for understanding the underlying biological mechanisms of tumor development and progression, as well as the potential for developing novel therapeutic approaches. Overall, WT1 recombinant protein research represents a significant intersection of developmental biology, oncology, and immunology, with the hope of translating these findings into effective clinical applications for cancer treatment.
